PMID- 25348235
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20181202
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 14
DP  - 2014 Oct 27
TI  - Tolterodine extended release in the treatment of male OAB/storage LUTS: a 
      systematic review.
PG  - 84
LID - 10.1186/1471-2490-14-84 [doi]
LID - 84
AB  - BACKGROUND: Overactive bladder (OAB)/ storage lower urinary tract symptoms (LUTS) 
      have a high prevalence affecting up to 90% of men over 80 years. The role of 
      sufficient therapies appears crucial. In the present review, we analyzed the 
      mechanism of action of tolterodine extended-release (ER) with the aim to clarify 
      its efficacy and safety profile, as compared to other active treatments of 
      OAB/storage LUTS. METHODS: A wide Medline search was performed including the 
      combination of following words: "LUTS", "BPH", "OAB", "antimuscarinic", 
      "tolterodine", "tolterodine ER". IPSS, IPSS storage sub-score and IPSS QoL 
      (International Prostate Symptom Score) were the validated efficacy outcomes. In 
      addition, the numbers of urgency episodes/24 h, urgency incontinence episodes/24 
      h, incontinence episodes/24 h and pad use were considered. We also evaluated the 
      most common adverse events (AEs) reported for tolterodine ER. RESULTS: Of 128 
      retrieved articles, 109 were excluded. The efficacy and tolerability of 
      tolterodine ER Vs. tolterodine IR have been evaluated in a multicenter, 
      double-blind, randomized placebo controlled study in 1529 patients with OAB. A 
      71% mean reduction in urgency incontinence episodes was found in the tolterodine 
      ER group compared to a 60% reduction in the tolterodine IR (p < 0.05). Few 
      studies evaluated the clinical efficacy of alpha-blocker/tolterodine combination 
      therapy. In patients with large prostates (prostate volume >29 cc) only the 
      combination therapy significantly reduced 24-h voiding frequency (2.8 vs. 1.7 
      with tamsulosin, 1.4 with tolterodine, or 1.6 with placebo). A recent 
      meta-analysis evaluating tolterodine in comparison with other antimuscarinic 
      drugs demonstrated that tolterodine ER was significantly more effective than 
      placebo in reducing micturition/24 h, urinary leakage episodes/24 h, urgency 
      episodes/24 h, and urgency incontinence episodes/24 h. With regard to adverse 
      events, tolterodine ER was associated with a good adverse event profile resulting 
      in the third most favorable antimuscarinic. Antimuscarinic drugs are the mainstay 
      of pharmacological therapy for OAB / storage LUTS; several studies have 
      demonstrated that tolterodine ER is an effective and well tolerated formulation 
      of this class of treatment. CONCLUSION: Tolterodine ER resulted effective in 
      reducing frequency urgency and nocturia and urinary leakage in male patients with 
      OAB/storage LUTS. Dry mouth and constipation are the most frequently reported 
      adverse events.
FAU - Gacci, Mauro
AU  - Gacci M
AD  - Department of Urology, University of Florence, Careggi Hospital, Viale S, Luca - 
      50134, Florence, Italy. maurogacci@yahoo.it.
FAU - Novara, Giacomo
AU  - Novara G
FAU - De Nunzio, Cosimo
AU  - De Nunzio C
FAU - Tubaro, Andrea
AU  - Tubaro A
FAU - Schiavina, Riccardo
AU  - Schiavina R
FAU - Brunocilla, Eugenio
AU  - Brunocilla E
FAU - Sebastianelli, Arcangelo
AU  - Sebastianelli A
FAU - Salvi, Matteo
AU  - Salvi M
FAU - Oelke, Matthias
AU  - Oelke M
FAU - Gravas, Stavros
AU  - Gravas S
FAU - Carini, Marco
AU  - Carini M
FAU - Serni, Sergio
AU  - Serni S
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20141027
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Cresols)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Urological Agents)
RN  - 33RU150WUN (Phenylpropanolamine)
RN  - 5T619TQR3R (Tolterodine Tartrate)
SB  - IM
MH  - Adrenergic alpha-Antagonists/therapeutic use
MH  - Benzhydryl Compounds/adverse effects/pharmacokinetics/*therapeutic use
MH  - Constipation/chemically induced
MH  - Cresols/adverse effects/pharmacokinetics/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*drug therapy
MH  - Male
MH  - Muscarinic Antagonists/adverse effects/pharmacokinetics/*therapeutic use
MH  - Phenylpropanolamine/adverse effects/pharmacokinetics/*therapeutic use
MH  - Tolterodine Tartrate
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy
MH  - Urological Agents/adverse effects/pharmacokinetics/*therapeutic use
MH  - Xerostomia/chemically induced
PMC - PMC4230346
EDAT- 2014/10/29 06:00
MHDA- 2015/07/03 06:00
PMCR- 2014/10/27
CRDT- 2014/10/29 06:00
PHST- 2014/05/18 00:00 [received]
PHST- 2014/09/29 00:00 [accepted]
PHST- 2014/10/29 06:00 [entrez]
PHST- 2014/10/29 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
PHST- 2014/10/27 00:00 [pmc-release]
AID - 1471-2490-14-84 [pii]
AID - 377 [pii]
AID - 10.1186/1471-2490-14-84 [doi]
PST - epublish
SO  - BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84.